<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7bf6446b-a127-4c1a-b601-857d786025dd"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">DiphenhydrAMINE Hydrochloride Injection, USP</content>
   </title>
   <effectiveTime value="20250430"/>
   <setId root="50df93bf-fe72-48f6-a02e-ea9a313d47c2"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="118546603" root="1.3.6.1.4.1.519.1"/>
            <name>Cardinal Health 107, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="985847bd-9c29-44ff-bda8-7fb03b5c3112"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20241224"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55154-9363" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Diphenhydramine Hydrochloride</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>diphenhydramine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="63323-664" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TC2D6JAD40" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIPHENHYDRAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="8GTS82S83M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DIPHENHYDRAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="CNTM">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="CNTM">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="5"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="55154-9363-5" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20020801"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040466" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20020801"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="f7f2e1d7-0ce7-41cd-97b2-450f600e6220">
               <id root="aac891fe-dd49-4060-86d9-12e03b7fbb59"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Rx only</paragraph>
               </text>
               <effectiveTime value="20221121"/>
            </section>
         </component>
         <component>
            <section ID="b07570ce-090c-444b-9a15-3385a9223466">
               <id root="8a92d561-d850-4156-9640-383f95a3bc22"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION:</title>
               <text>
                  <paragraph>Diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride. It occurs as a white, crystalline powder, is freely soluble in water and alcohol.</paragraph>
                  <paragraph>The structural formula is as follows:</paragraph>
                  <renderMultiMedia ID="f01" referencedObject="MM1"/>
                  <paragraph>
                     <content styleCode="bold">C<sub>17</sub>H<sub>21</sub>NO•HCl                         M.W. 291.82</content>
                  </paragraph>
                  <paragraph>Diphenhydramine hydrochloride in the parenteral form is a sterile, pyrogen-free solution available in a concentration of 50 mg of diphenhydramine hydrochloride per mL. pH 4.0 to 6.5; sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dip0b-0001-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="c1b175d6-68f7-4e86-9b42-69ce496866ce">
               <id root="3c24d529-3e68-4b39-ba7d-25bd81148b1f"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY:</title>
               <text>
                  <paragraph>Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells. </paragraph>
                  <paragraph>Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine hydrochloride is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of diphenhydramine hydrochloride injection is not available.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="f78ee935-d9f9-4758-9a53-c95ba87aa74e">
               <id root="c07b2c3c-27c9-4db3-b9cc-5eaef6ce9ed9"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE:</title>
               <text>
                  <paragraph>Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="f5ff7266-2117-4424-b9f7-6832162a3a21">
                     <id root="5a7ccb9f-bc01-4cbd-b540-725c0efd0c3c"/>
                     <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
                     <title>
                        <content styleCode="italics">Antihistaminic</content>
                     </title>
                     <text>
                        <paragraph>For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.</paragraph>
                     </text>
                     <effectiveTime value="20221121"/>
                  </section>
               </component>
               <component>
                  <section ID="a339bbf4-7e02-46da-b0f8-f362540185c9">
                     <id root="8b86b28f-1e4f-4aa2-af04-bb81cb49c878"/>
                     <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
                     <title>
                        <content styleCode="italics">Motion Sickness</content>
                     </title>
                     <text>
                        <paragraph>For active treatment of motion sickness.</paragraph>
                     </text>
                     <effectiveTime value="20221121"/>
                  </section>
               </component>
               <component>
                  <section ID="cee95d0b-de38-4af1-a976-386750e8e316">
                     <id root="db61c932-e3b6-4e01-9165-909462460b4a"/>
                     <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
                     <title>
                        <content styleCode="italics">Antiparkinsonism</content>
                     </title>
                     <text>
                        <paragraph>For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="fa9d0f12-b8af-484a-9ae2-ef935ccdeed0">
               <id root="3889d8a8-3075-4af8-98aa-d46d6c8768c8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS:</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="c85549f9-4208-4c80-9c8a-44dcdeb0e29c">
                     <id root="acc1a772-a02b-4347-ae64-261499dc3345"/>
                     <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
                     <title>
                        <content styleCode="italics">Use in Neonates or Premature Infants</content>
                     </title>
                     <text>
                        <paragraph>This drug should <content styleCode="italics">not </content>be used in neonates or premature infants.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="d0f79ee6-5a7a-441b-89cd-98da2da76b11">
                     <id root="2c4cc3cd-f013-4832-b133-0b12e460e807"/>
                     <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
                     <title>
                        <content styleCode="italics">Use in Nursing Mothers</content>
                     </title>
                     <text>
                        <paragraph>Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.</paragraph>
                     </text>
                     <effectiveTime value="20221121"/>
                  </section>
               </component>
               <component>
                  <section ID="c2988325-5121-4d64-b940-2dffca6a1a95">
                     <id root="27eeb3de-ee01-4322-a914-277ab6e60561"/>
                     <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
                     <title>
                        <content styleCode="italics">Use as a Local Anesthetic</content>
                     </title>
                     <text>
                        <paragraph>Because of the risk of local necrosis, this drug should not be used as a local anesthetic. <content styleCode="bold">Antihistamines are also contraindicated in the following conditions: </content>
                        </paragraph>
                        <paragraph>Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="dea1384c-9acd-46ab-bb6d-ef74b7da9831">
               <id root="fa6f79bc-10b4-430d-86d8-1b4bd5e2e94d"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS:</title>
               <text>
                  <paragraph>Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction. </paragraph>
                  <paragraph>Local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine hydrochloride.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="f464da6b-833c-435a-9756-4695d98ca630">
                     <id root="6a001764-f800-44e4-8053-1e952d8e2e7b"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>
                        <content styleCode="italics">Use in Pediatric Patients</content>
                     </title>
                     <text>
                        <paragraph>In pediatric patients, especially, antihistamines in <content styleCode="italics">overdosage </content>may cause hallucinations, convulsions, or death.</paragraph>
                        <paragraph>As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="df221f8e-3c0d-490a-8e55-515d3012e266">
                     <id root="c601ad24-952c-4c61-bcb6-6d709ed7cf2b"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>
                        <content styleCode="italics">Use in the Elderly (approximately 60 years or older)</content>
                     </title>
                     <text>
                        <paragraph>Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.</paragraph>
                     </text>
                     <effectiveTime value="20221121"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="e91659bb-8292-48f5-b7c0-b920d0b9f24c">
               <id root="99d26140-020d-4ab2-9aee-4760c1e3d760"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS:</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="cabf6cda-433f-49df-b3c5-52e380d53003">
                     <id root="5c795d82-a92d-46d6-a3ef-6191a3dec120"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>
                        <content styleCode="italics">General</content>
                     </title>
                     <text>
                        <paragraph>Diphenhydramine hydrochloride has an atropine-like action and, therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease including asthma.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ee99c6f7-cfb3-40b3-a805-f0067a9dd5e1">
                     <id root="71fcd5d7-2fdf-43ab-b597-defcdbf92404"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>
                        <content styleCode="italics">Information for Patients</content>
                     </title>
                     <text>
                        <paragraph>Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol.</paragraph>
                        <paragraph>Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.</paragraph>
                     </text>
                     <effectiveTime value="20221121"/>
                  </section>
               </component>
               <component>
                  <section ID="a3858c5c-03c9-480e-84b8-2c2a56d971e7">
                     <id root="2ebcd371-5e84-4cca-9d42-489c0ebaf78e"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>
                        <content styleCode="italics">Drug Interactions</content>
                     </title>
                     <text>
                        <paragraph>Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). </paragraph>
                        <paragraph>MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.</paragraph>
                     </text>
                     <effectiveTime value="20221121"/>
                  </section>
               </component>
               <component>
                  <section ID="e081e763-0649-44cf-9db3-1400571b7cc8">
                     <id root="0c00ac89-5e75-4848-9504-3139e98aac35"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>
                        <content styleCode="italics">Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.</paragraph>
                     </text>
                     <effectiveTime value="20221121"/>
                  </section>
               </component>
               <component>
                  <section ID="a4b865ea-cf4c-4076-b0c6-819f60ad7daa">
                     <id root="fbe1cbc9-7781-4fc6-ad40-37cd135867ca"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>
                        <content styleCode="italics">Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Pregnancy Category B. </content>Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ada33088-50ee-4528-8abd-5b13db1121e2">
                     <id root="333184ab-17a5-46c4-b08b-9b6a66dcebe7"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>
                        <content styleCode="italics">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Diphenhydramine hydrochloride should not be used in neonates and premature infants (see <content styleCode="bold">
                              <linkHtml href="#fa9d0f12-b8af-484a-9ae2-ef935ccdeed0">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Diphenhydramine hydrochloride may diminish mental alertness, or, in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions, or death (see <content styleCode="bold">
                              <linkHtml href="#dea1384c-9acd-46ab-bb6d-ef74b7da9831">WARNINGS</linkHtml>
                           </content> and <content styleCode="bold">
                              <linkHtml href="#c45275c0-cc86-4a3b-b517-7e4343db3c01">OVERDOSAGE</linkHtml>
                           </content>).</paragraph>
                        <paragraph>See also <content styleCode="bold">
                              <linkHtml href="#a3710416-5a70-46c6-b64c-e150e39a8bca">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content> section.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="e8e54305-cca7-4252-961e-a22c6f17809a">
               <id root="1626c8bc-4a85-41f9-8a3e-f1531d0144e1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS:</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The most frequent adverse reactions are underscored.</content>
                  </paragraph>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>
                        <content styleCode="italics">General: </content>Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.</item>
                     <item>
                        <caption>2.</caption>
                        <content styleCode="italics">Cardiovascular System: </content>Hypotension, headache, palpitations, tachycardia, extrasystoles.</item>
                     <item>
                        <caption>3.</caption>
                        <content styleCode="italics">Hematologic System: </content>Hemolytic anemia, thrombocytopenia, agranulocytosis.</item>
                     <item>
                        <caption>4.</caption>
                        <content styleCode="italics">Nervous System: </content>
                        <content styleCode="underline">Sedation</content>, <content styleCode="underline">sleepiness</content>, <content styleCode="underline">dizziness</content>, <content styleCode="underline">disturbed coordination</content>, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions.</item>
                     <item>
                        <caption>5.</caption>
                        <content styleCode="italics">GI System: </content>
                        <content styleCode="underline">Epigastric distress</content>, anorexia, nausea, vomiting, diarrhea, constipation.</item>
                     <item>
                        <caption>6.</caption>
                        <content styleCode="italics">GU System: </content>Urinary frequency, difficult urination, urinary retention, early menses.</item>
                     <item>
                        <caption>7.</caption>
                        <content styleCode="italics">Respiratory System: </content>
                        <content styleCode="underline">Thickening of bronchial secretions</content>, tightness of chest or throat and wheezing, nasal stuffiness.</item>
                  </list>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="c45275c0-cc86-4a3b-b517-7e4343db3c01">
               <id root="3842c032-8744-4894-9ced-e40fcd38ed53"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE:</title>
               <text>
                  <paragraph>Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms; dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Stimulants </content>should not be used.</paragraph>
                  <paragraph>Vasopressors may be used to treat hypotension.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="a3710416-5a70-46c6-b64c-e150e39a8bca">
               <id root="230e510d-9a2d-4e81-a15e-af2826d8a7d1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION:</title>
               <text>
                  <paragraph>THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY.</paragraph>
                  <paragraph>Diphenhydramine hydrochloride in the injectable form is indicated when the oral form is impractical.</paragraph>
                  <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                  <paragraph>DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pediatric Patients, other than premature infants and neonates: </content>5 mg/kg/24 hr or 150 mg/m<sup>2</sup>/24 hr. Maximum daily dosage is 300 mg. Divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Adults: </content>10 to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly, 100 mg if required; maximum daily dosage is 400 mg.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="c17c3341-7cc9-417c-ab7e-3a6105ad96f7">
               <id root="085a5d48-9ee7-4937-914a-5420c61760b7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED:</title>
               <text>
                  <paragraph>DiphenhydrAMINE Hydrochloride Injection, USP in parenteral form is supplied as:</paragraph>
                  <table width="98.18%">
                     <col width="41%"/>
                     <col width="30%"/>
                     <col width="25%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Unit of Sale</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Strength</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Each</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Overbagged with 5 x 1 mL single dose vial in each bag, NDC 55154-9363-5</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>50 mg per mL</paragraph>
                              <paragraph>1 mL fill in a 2 mL vial.</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>1 mL Single Dose Vial</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>It is supplied as a sterile, pyrogen-free solution containing 50 mg diphenhydramine hydrochloride in each milliliter of solution.<br/>
                  </paragraph>
                  <paragraph>The container closure is not made with natural rubber latex.<br/>
                  </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].<br/>
                  </paragraph>
                  <paragraph>Protect from light.  Keep from freezing. <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="a43a00c4-508c-4f26-840c-fb7f7a14a7fe">
               <id root="281ee667-7cce-44a6-8e32-3573ef61baab"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <renderMultiMedia ID="f02" referencedObject="MM2"/>
                  <paragraph>
                     <linkHtml href="http://www.fresenius-kabi.com/us">www.fresenius-kabi.com/us</linkHtml>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed By:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardinal Health </content>
                  </paragraph>
                  <paragraph>Dublin, OH 43017</paragraph>
                  <paragraph>L35116230425</paragraph>
                  <paragraph>
                     <br/>
                     <br/>45954E</paragraph>
                  <paragraph>Revised: October 2024<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dip0b-0001-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_08b9351b-96fa-40e3-b3f8-bde1915bb025">
               <id root="3d43df90-74c8-4d0a-90bc-f63f971d44b1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel </title>
               <text>
                  <paragraph>NDC 55154-9363-5</paragraph>
                  <paragraph>
                     <content styleCode="bold">DiphenhydrAMINE HYDROCHLORIDE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">INJECTION, USP 50 mg per mL</content>
                  </paragraph>
                  <paragraph>HIGH POTENCY</paragraph>
                  <paragraph>5 x 1 mL SINGLE DOSE VIALS</paragraph>
                  <renderMultiMedia ID="id-1646111883" referencedObject="ID_8332b1ce-5ace-49af-8c34-96bf750f1b56"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="ID_8332b1ce-5ace-49af-8c34-96bf750f1b56">
                     <text>50mg/mL bag label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="6d3fc323-76a2-4dd8-84ef-2944e25da3b3-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>